Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Market Cap	212.23B -10.7%
Revenue (ttm)	272.42B +1.4%
Net Income	6.90B -23.6%
EPS	375.00 -23.5%
Shares Out	17.92M
PE Ratio	31.57
Forward PE	n/a
Dividend	155.00 (1.34%)
Ex-Dividend Date	Dec 29, 2025

Volume	93,334
Average Volume	113,865
Open	11,620
Previous Close	11,580
Day's Range	11,520 - 11,870
52-Week Range	10,780 - 16,240
Beta	0.63
RSI	46.40
Earnings Date	May 13, 2026

About KRX:007570

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and be...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 666
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 007570

Financial Performance

In 2025, KRX:007570's revenue was 272.42 billion, an increase of 1.39% compared to the previous year's 268.68 billion. Earnings were 6.90 billion, a decrease of -23.55%.